21:35 , Jan 11, 2019 |  BioCentury  |  Emerging Company Profile

Artios: Probing DNA Damage

With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA damage response programs that could improve upon PARP inhibitors -- and the funds to take them to...
18:56 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
06:02 , Aug 10, 2018 |  BC Extra  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
21:09 , May 1, 2018 |  BC Innovations  |  Translation in Brief

Rewriting cancer’s origin story

A collection of 29 papers published across a suite of Cell journals in April by The Cancer Genome Atlas (TCGA) consortium completed the Pan-Cancer Atlas -- a comprehensive analysis of molecular signatures across cancer types....
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
22:18 , Jun 23, 2017 |  BioCentury  |  Finance

Synthetic vitality

Versant Ventures and MPM Capital backed Repare Therapeutics Inc. with 2017’s largest series A round to get the synthetic lethality play to clinical proof of concept and possibly an exit. Repare emerged from stealth mode...
19:39 , Jun 23, 2017 |  BC Week In Review  |  Financial News

Repare launches with $68M series A

On June 22, cancer company Repare Therapeutics Inc. (Montreal, Quebec) launched with a $68 million series A round. Versant Ventures , which founded the company, co-led the round with MPM Capital. Also participating were Fonds...
11:45 , Jun 22, 2017 |  BC Extra  |  Financial News

Repare launches with $68M

Repare Therapeutics Inc. (Montreal, Quebec) launched with a $68 million series A round. Versant Ventures , which founded the company, co-led the round with MPM Capital. Also participating were Fonds de solidarité FTQ, the Celgene...
11:03 , Jun 22, 2017 |  BC Innovations  |  Emerging Company Profile

Repare in progress

With a $68 million series A co-led by Versant Ventures and MPM Capital, Repare Therapeutics Inc. emerged from 18 months of stealth today, making a splash in the growing pool of newcos targeting cancer via...
07:00 , Sep 26, 2016 |  BioCentury  |  Finance

Damage control

SV Life Sciences is going back for seconds in DNA damage repair, leading a $33.2 million series A round for Artios Pharma Ltd. This time, the firm is building the company for the long term...